Khan Omar
Multiple Sclerosis Center and Neuroimaging Laboratory, Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Neurology. 2007 May 29;68(22 Suppl 3):S64-71; discussion S91-6. doi: 10.1212/01.wnl.0000275235.43506.d2.
Neuroprotection is a difficult concept to define in the context of multiple sclerosis (MS), a complex heterogeneous disease with an uncertain immunopathogenetic mechanism. Although treatment and natural history studies use clinical determinants and MRI metrics to assess disability, long-term progression, and the effects of disease-modifying drugs, the association between clinical and imaging outcomes is relatively modest. In the future, a composite measure comprising both clinical and imaging markers, along with investigational surrogates derived from molecular genetics and proteomics, may provide an accurate quantitative measure of neuroprotection. However, a consensus definition of "neuroprotection" applicable to MS needs to be established before such a tool can be validated and put to use.
在多发性硬化症（MS）的背景下，神经保护是一个难以定义的概念。MS是一种复杂的异质性疾病，其免疫发病机制尚不确定。尽管治疗和自然史研究使用临床指标和MRI指标来评估残疾、长期进展以及疾病修饰药物的效果，但临床和影像学结果之间的关联相对较弱。未来，一种综合了临床和影像学标志物以及源自分子遗传学和蛋白质组学的研究替代指标的测量方法，可能会提供一种准确的神经保护定量测量方法。然而，在这样一种工具能够得到验证并投入使用之前，需要先建立一个适用于MS的“神经保护”的共识定义。
